NCT03113851 Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer |
Lung cancer metastatic |
RT 35Gy / 10 fractions |
China |
|
|
IT rhGM-CSF |
|
NCT03323424 Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM) |
Breast, colorectal, or upper aerodigestive tract metastatic |
SBRT for metastasis: 45Gy / 3 fractions (hepatic and pulmonary) 27Gy / 3 fractions (bone) 33Gy / 3 fractions (intra-cranial) |
France |
|
|
IT Therapies capable of ADCC |
|
NCT02542137 Abscopal Effect for Metastatic Small Cell Lung Cancer |
Small cell lung cancer |
RT 35Gy / 10 fractions |
China |
|
|
IT Thymosin-α-1 |
|
NCT02535988 Abscopal Effect for Metastatic Colorectal Cancer |
Metastatic colorectal cancer |
RT 35Gy / 10 fractions |
China |
|
|
IT Thymosin-α-1 |
|
NCT02542930 Abscopal Effect for Metastatic Non-small Cell Lung Cancer |
Non-small cell lung cancer |
RT 35Gy / 10 fractions |
China |
|
|
IT Thymosin-α-1 |
|
NCT03354962 Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors |
Melanoma |
RT SBRT (recommended optimal dose) |
France |
|
|
IT Anti PD-1 + anti-CTLA-4 |
|
NCT02334709 Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. |
Renal cell carcinoma |
SBRT (3 dose levels): 24Gy / 3 fractions 30Gy / 3 fractions 36Gy / 3 fractions |
Belgium |
|
|
IT TKIs |
|
NCT02623595 A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy |
Non-small cell lung cancer |
RT SBRT 50Gy / 5 fractions |
China |
|
|
IT rhGM-CSF |
|
NCT02406183 Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma |
Melanoma |
RT SBRT (3 dose levels): 24Gy / 3 fractions 30Gy / 3 fractions 36Gy / 3 fractions |
Belgium |
|
|
IT anti-CTLA-4 |
|
NCT02830594 Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer |
Metastatic esophageal, stomach, or gastroesophageal junction cancer |
RT SBRT (3 dose levels): 24Gy / 3 fractions 30Gy / 3 fractions 36Gy / 3 fractions |
United States |
|
|
IT Anti-PD-1 |
|
NCT02562625 Trial of Pembrolizumab and Radiotherapy in Melanoma (PERM) |
Melanoma |
RT 24Gy / 3 fractions |
England |
|
|
IT Anti-PD-1 |
|
NCT02538471 LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer |
Metastatic breast cancer |
RT 22.5Gy / 3 fractions |
United States |
|
|
IT TGF-β receptor type-1 kinase inhibitor |
|
NCT02976740 SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy |
Metastatic lung cancer |
RT SBRT 50Gy / 4-10 fractions |
China |
|
|
IT rhGM-CSF |
|
NCT02115139 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (GRAY-B) |
Melanoma |
RT 30Gy / 10 fractions (whole brain) |
Spain |
|
|
IT anti-CTLA-4 |
|